Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 6, Issue 5, 2007, Pages 327-333

  Touw, D J ^a   Knox, A J ^b   Smyth, A ^c  

^a Apotheek Haagse Ziekenhuizen   (Netherlands)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Diurnal variation; Pharmacokinetics; Tobramycin

Indexed keywords

TOBRAMYCIN;

ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; CIRCADIAN RHYTHM; CONTROLLED STUDY; CREATININE CLEARANCE; CYSTIC FIBROSIS; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; FEMALE; HUMAN; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; POPULATION MODEL; POST HOC ANALYSIS; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; MODELS, THEORETICAL; RETROSPECTIVE STUDIES; TOBRAMYCIN;

EID: 34548266667     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2006.12.007     Document Type: Article

References (28)

1. Döring G., Conway S.P., Heijerman H.G.M., Hodson M.E., Høiby N., Smyth A., and Touw D.J. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 16 (2000) 749-767
2. Smyth A., Tan K.H.-V., Hyman-Taylor P., et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations in cystic fibrosis - the TOPIC study, a randomised controlled trial. Lancet 365 (2005) 573-578
3. Van Lent-Evers N.A., Mathot R.A., Geus W.P., van Hout B.A., and Vinks A.A. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit 21 (1999) 63-73
4. Touw D.J., Vinks A.A.T.M.M., Mouton J.W., and Horrevorts A.M. Pharmacokinetic optimisation of antibiotics in cystic fibrosis. Present practice and future directions. Clin Pharmacokinetics 35 (1998) 437-459
5. Ngui-Yen J.H., Doyle P.W., and Smith J.A. Comparative analysis of two rapid, automated methods for determining aminoglycoside levels. J Clin Microbiol 20 (1984) 962-965
6. Proost J.H., and Meijer D.K.F. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 22 (1992) 155-163
7. Schwartz G.J., Haycock G.B., Edelman C.M., et al. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58 (1976) 259-263
8. Jelliffe R.W. Estimation of creatinine clearance when urine cannot be collected. Lancet (1971) 975-976 i
9. Touw D.J., Vinks A.A.T.M.M., and Neef C. Pharmacokinetic modelling of intravenous tobramycin in adolescent and adult patients with cystic fibrosis using the nonparametric expectation maximization (NPEM) algorithm. Pharm World Sc 19 (1997) 147-158
10. Ng P.K. Determining aminoglycoside dosage and blood levels using a programmable calculator. Am J Hosp Pharm 37 (1980) 225-231
11. Vandenbussche H.L., and Klepser M.E. Single daily dosing of tobramycin in cystic fibrosis: is it better for the patients or for the bugs?. Lancet 365 (2005) 547-548
12. Smyth A., Touw D.J., Tan K.H.-V., Bertenshaw C., and Stableforth D. Tobramycin dosing in cystic fibrosis. Lancet 365 (2005) 1767-1768
13. Aminimanizani A., Beringer P.M., Kang J., Tsang L., Jelliffe R.W., and Shapiro B.J. Distribution and elimination of tobramycin after administration in single or multiple daily doses in adult patients with cystic fibrosis. J Antimicr Chemother 50 (2002) 553-559
14. Bates R.D., Nahata M.C., Jones J.W., McCoy K., Young G., Cox S., et al. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. Chest 112 (1997) 1208-1213
15. Touw D.J., and Bos J.M. Development of gentamicin population parameters in paediatric patients [abstract]. Ther Drug Monit 19 (1997) 570
16. Prins J.M., Büller H.R., Kuijper E.J., Tange R.A., and Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet 341 (1993) 335-339
17. Vinks A.A., Den Holander J.G., Overbeek S.E., Jelliffe R.W., and Mouton J.W. Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis. Antimicrob Agents Chemother 47 (2003) 541-547
18. Contrepois A., Brion N., Garaud J.J., Faurisson F., Delatour F., Levy J.C., Deybach J.C., and Carbon C. Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans. Antimicrob Agents Chemother 27 (1985) 520-524
19. Bragonier R., and Brown N.M. The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis. J Antimicr Chemother 42 (1998) 103-106
20. Koopman M.G., Koomen G.C., Krediet R.T., De Moor E.A., Hoek F.G., and Arisz L. Circadian rhythm of glomerular filtration rate in normal individuals. Clin Sci 77 (1989) 105-111
21. Prins J.M., Weverling G.J., Van Ketel R.J., and Speelman P. Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients. Clin Pharmacol Ther 62 (1997) 106-111
22. Rougier F., Claude D., Maurin M., et al. Aminoglycoside nephrotoxicity: modeling, simulation and control. Antimicrob Agents Chemother 47 (2003) 1010-1016
23. Vinks A.A.T.M.M., Mouton J.W., Touw D.J., Heijerman H.G.M., Danhof M., and Bakker W. Population pharmacokinetics of ceftazidime in cystic fibrosis patients by using a nonparametric algorithm and optimal sampling strategy. Antimicrob Agents Chemother 40 (1996) 1091-1097
24. Elting L., Bodey G.P., Rosenbaum B., and Fainstein V. Circadian variation in serum amikacin levels. J Clin Pharmacol 30 (1990) 798-801
25. Bleyzac N., Alard-Latour B., Laffont A., Mouret J., Jelliffe R., and Maire P. Diurnal changes in the pharmacokinetic behavior of amikacin. Ther Drug Monit 22 (2000) 307-312
26. Lucht F., Tigaud S., Esposito G., Cougnard J., Fargier M.P., Peyramond D., et al. Chronokinetic study of netilmicin in man. Eur J Clin Pharmacol 39 (1990) 199-201
27. Fauvelle F., Perrin P., Belfayol L., et al. Fever and associated changes in glomerular filtration rate erase anticipated diurnal variations in aminoglycoside pharmacokinetics. Antimicrob Agents Chemother 38 (1994) 620-623
28. Dickson C.J., Schwartzman M., and Bertino J.S. Factors affecting aminoglycoside disposition: effects of circadian rhythm and dietary protein intake on gentamicin pharmacokinetics. Clin Pharmacol Ther 39 (1986) 325-328